Filing and business context
Filing identity: The supplied filing is Eyenovia, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 31, 2023. This does not match the request metadata naming HYPERION DEFI, INC.; verify the issuer before relying on this summary. The filing reports annual results, not standalone 2022 fourth-quarter results.
Eyenovia is a pre-commercial ophthalmic technology company developing the Optejet drug-delivery device and related therapies: Mydcombi for pupil dilation, MicroLine for presbyopia, and MicroPine for pediatric progressive myopia. It had no product sales revenue and no product approved for sale at year-end.
Financial performance and liquidity
| Metric | FY 2022 / Dec. 31, 2022 | FY 2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | $0 | $14.0 million |
| Cost of revenue | $0 | $1.6 million |
| Research and development | $13.4 million | $14.9 million |
| General and administrative | $13.5 million | $10.6 million |
| Operating loss | $26.9 million | $13.0 million |
| Net loss | $28.0 million | $12.8 million |
| Net loss per share, diluted | $0.83 | $0.49 |
| Cash used in operating activities | $25.1 million | $20.9 million |
| Cash and cash equivalents | $22.9 million | $19.5 million |
| Working capital | $23.1 million | $10.8 million |
| Gross notes payable | $10.4 million | $7.5 million |
FY 2021 revenue was primarily upfront licensing income: $10.0 million from Bausch + Lomb and $4.0 million recognized from Arctic Vision. No revenue was recognized in 2022. Accordingly, a product-sales margin is not meaningful for 2022; the filing does not report a 2022 gross margin.
Year-end total assets were $31.0 million and total liabilities were $13.8 million. Avenue debt had $10.425 million gross principal and final-payment amounts outstanding, with an $8.731 million net carrying value after debt discounts. The loan is secured by substantially all company assets, including intellectual property. Its stated maturity is November 1, 2025; up to an additional $5 million was available subject to conditions.
Material changes versus the prior year
- Revenue fell from $14.0 million to zero as prior-year licensing performance obligations were completed and no new revenue was earned.
- Net loss more than doubled, from $12.8 million to $28.0 million; loss per share increased from $0.49 to $0.83.
- Operating cash use increased to $25.1 million from $20.9 million. Cash and cash equivalents increased to $22.9 million from $19.5 million, but 2021 included $7.9 million of restricted cash that was used to repay the SVB loan in 2022.
- R&D expense declined 10% to $13.4 million, partly because Bausch + Lomb assumed control and costs of the MicroPine trial and VISION-2 cost less than VISION-1. G&A expense rose 27% to $13.5 million, including higher personnel, stock compensation, and professional fees.
- Interest expense rose to $1.38 million from $0.39 million, reflecting the SVB loan payoff and Avenue financing. Eyenovia repaid its $7.5 million SVB loan in November 2022 and entered into the Avenue facility later that month.
- Shares issued and outstanding rose to 36.7 million from 28.4 million, reflecting equity offerings and financing-related issuances.
Outlook, risks and notable items
- Going concern: Management and the auditor report substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance of the financial statements, absent additional funding. Management says it may need to raise capital or complete licensing or business-development transactions; failure could require cuts to R&D and other costs. The company has incurred losses since inception and accumulated a $118.2 million deficit.
- Runway and obligations: The filing reports $22.9 million of year-end cash and $25.1 million of annual operating cash use. Near-term commitments include $3.7 million of year-end payables and accruals, $0.5 million of lease payments, potential executive severance of $1.0 million, and $0.4 million of debt payments. Management does not provide a clear quantified cash-runway forecast.
- Mydcombi: The FDA accepted the resubmitted NDA in December 2022 after a 2021 complete response letter related in part to classification of the dispenser as a device constituent of a drug-device combination product. The PDUFA target action date was May 8, 2023; that date is a stated target, not an approval assurance.
- MicroLine: Eyenovia reported positive top-line VISION-2 results in fourth-quarter 2022 and expected a pre-NDA meeting in April 2023. MicroLine is also licensed to Arctic Vision in Greater China and South Korea.
- MicroPine: Bausch + Lomb assumed sponsorship and responsibility for the CHAPERONE study and U.S./Canada development. Eyenovia may receive up to $35 million in regulatory and launch milestones, plus tiered royalties; timing and receipt are uncertain.
- Licensing: Arctic Vision may owe up to approximately $37.7 million in remaining milestones, with the company anticipating performance obligations between late 2024 and late 2025. Royalties had not been earned by year-end. A portion of certain Arctic Vision proceeds is payable to Senju.
- Other financing and developments: Subsequent to year-end, the company reported approximately $3.5 million of net proceeds from ATM share sales. In February 2023 it announced a development collaboration with Formosa Pharmaceuticals to assess Optejet delivery of Formosa’s formulations.
- Key risks: Dependence on further financing and successful regulatory review; no commercial track record; manufacturing and third-party supply reliance; competition (including Vuity for presbyopia); reimbursement, adoption, and pricing uncertainty; potential dilution; and patent challenges. Three instituted inter partes review proceedings challenge Sydnexis patents, with final decisions expected by July 15, 2023.
- The auditor issued an unmodified opinion on the financial statements with a going-concern explanatory paragraph. Management reported disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not provide an internal-control attestation.
Most important facts to verify
- Confirm issuer identity: the filing is for Eyenovia, Inc. (ticker EYEN), not HYPERION DEFI, INC.
- Check the FDA’s actual decision and current status of the Mydcombi NDA after its May 8, 2023 target date.
- Verify subsequent financing, cash balance, and current runway; year-end cash was below FY 2022 operating cash use and management disclosed substantial going-concern doubt.
- Review Avenue loan terms, collateral, covenants, conversion provisions, and whether the additional $5 million tranche was drawn.
- Confirm final VISION-2 results and the regulatory path for MicroLine, and the status, funding, and milestones of the Bausch and Arctic Vision programs.
- Assess dilution from ATM sales, outstanding warrants and options, and any later equity or debt financing.